Home Site Map Contact Us Join ASA Members Only
 
ASA NEWSLETTER
 
 
September 1996
Volume 60
Number 9
 
WASHINGTON REPORT

Congress Passes Insurance Portability Legislation

Michael Scott, Director
Governmental and Legal Affairs
E-mail the author



An agreement in late July between Rep. Bill Archer (R-TX) and Sen. Edward M. Kennedy (D-MA) on provisions of the bill relating to medical savings accounts (MSAs) cleared the way for appointment of conferees on the long-stalled insurance portability legislation and ultimate passage of the bill in early August by both houses. President Clinton is expected to sign the bill promptly.

Members of both parties claimed credit for the bill. The portability provisions were essentially drawn from the President's health reform proposal of two years ago, which died in the face of savage opposition by the insurance industry and represented a major factor in the GOP gaining control of the Congress last year.

Congressional Republicans, on the other hand, emphasized their ability to work out portability terms acceptable to the insurance industry and to business interests. Principal architects of the legislation were Sens. Kennedy and Nancy Kassebaum (R-KS), Chair of the Senate Labor and Human Resources Committee, who is retiring this year.

The principal impediment to earlier passage of the legislation was the insistence of House Republicans that at least an experimental program for MSAs be included. An effort by Sen. Robert Dole, prior to his retirement from the Senate on June 11, to include an MSA provision in the Senate version had been narrowly defeated, which bore heavily on the controversy over appointment of Senate conferees when Democrats claimed he planned to "stack" the conference with pro-MSA senators. The Archer-Kennedy negotiations resulted in the development of a compromise four-year experiment involving not more than 750,000 employees of small firms or self-employed individuals.

Of major interest to ASA members, the final legislation contains language advocated by organized medicine, including ASA, that addresses fraud and abuse, requiring that a provider act "knowingly and willfully" before criminal sanctions could be imposed and that the government provide binding advisory opinions on fraud and abuse issues when advice is requested by a provider.

Practice Expense Extension Introduced in House

During the latter half of July, the ASA Washington Office was active in generating support for H.R. 3859, introduced by Reps. Edward Whitfield (R-KY) and Ralph M. Hall (D-TX), the effect of which would be to extend the effective date for implementing new resource-based practice expense values under the Medicare Fee Schedule by one year, to January 1, 1999.

Impetus for the proposed legislation was the Health Care Financing Administration (HCFA) announcement that it had fallen behind in surveying indirect physician practice costs and that "proxy" data would be used in-stead in preparing a proposed schedule of practice expense values for public review and comment next spring.

Along with several other members of the Practice Expense Coalition, ASA successfully lobbied the AMA House of Delegates to adopt a resolution favoring delay in the practice ex-pense implementation date. Since then, ASA legislative representatives and key contacts have been in touch with numerous congressional offices, seeking sponsors for the bill. The only apparent vehicle for the proposal in the present Congress is believed to be the omnibus Continuing Resolution for FY 1997, expected to be considered in September prior to recess for the elections.

Patent Bill Passes House

By more than a 2-to-1 margin, the House adopted on July 24 an amendment to one of the FY 1997 appropriations bills that would forbid the Patent and Trademark Office from using funds for the issuance of medical process patents.

The amendment, originally introduced in slightly different form by Rep. Greg Ganske (R-IA) as H.R. 1127, had received strong support from the medical community, including ASA, in the wake of recently settled patent infringement litigation relating to an ophthalmic surgical procedure.

The Ganske amendment was vigorously opposed by the biotechnology industry, which was concerned about the impact of the ban on the patentability of biotechnological processes such as gene therapy. Although somewhat appeased by last-minute revisions to the amendment designed to protect the industry, biotechnological company spokespeople still objected to the form of the bill, expressing preference for the concept of a similar bill (S. 1334) introduced last year in the Senate by Sen. Bill Frist (R-TN). Negotiations concerning the terms of the Frist bill had stalled in recent weeks, and it is hoped that House passage of the Ganske version would give impetus to further discussions.

Both Sen. Frist and Rep. Ganske practiced surgery prior to their election in late 1994.

Commerce Committee Reports Gag Clause Ban

On the same day the House adopted his patent bill, Rep. Ganske succeeded in gaining unanimous House Commerce Committee approval of his bill (H.R. 2976) prohibiting managed care organizations from placing limits on communications (so-called "gag rules") between providers and their patients. The bill, expected to be brought to the House floor in September, received strong support from the Patient Access to Specialty Care Coalition, in which ASA is an active participant.

 


return to top Home >Newsletters >September 1996Home >Test


 


FEATURES

A Demonstration of Historic Proportions

ARTICLES


DEPARTMENTS


The views expressed herein are those of the authors and do not necessarily represent or reflect the views, policies or actions of the American Society of Anesthesiologists.

NL Archives

Information for Authors